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Despite the discovery and development of novel therapies, cancer is still a leading cause
of death worldwide. In order to grow, tumor cells require large quantities of nutrients
involved in metabolic processes, and an increase in iron levels is known to contribute to
cancer proliferation. Iron plays an important role in the active site of a number of proteins
involved in energy metabolism, DNA synthesis and repair, such as ribonucleotide
reductase, which induce G0/S phase arrest and exert a marked antineoplastic effect,
particularly in leukemia and neuroblastoma. Iron-depletion strategies using iron chelators
have been shown to result in cell cycle arrest and apoptosis. Deferoxamine (DFO) was
the first FDA-approved drug for the treatment of iron overload pathologies, and has
also been recognized as having anticancer properties. The high cost, low permeability
and short plasma half-life of DFO led to the development of other iron-chelating
drugs. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs chelate cellular iron by
tridentate binding, and inhibit DNA synthesis more robustly than DFO, demonstrating
an effective antiproliferative activity. Here, we investigated the biological effects of a
PIH derivative, 3-chloro-N′-(2-hydroxybenzylidene)benzohydrazide (CHBH), known to
be a lysine-specific histone demethylase 1A inhibitor. We showed that CHBH is able to
induce cell proliferation arrest in several human cancer cell lines, including lung, colon,
pancreas and breast cancer, at micromolar levels. Our findings indicate that CHBH
exerts a dual anticancer action by strongly impairing iron metabolism and modulating
chromatin structure and function.
Keywords: novel therapies, cancer, epigenetics, iron chelating agent, chromatin remodeling
INTRODUCTION
Despite continuous advances in screening, prevention and therapy, cancer remains a leading
cause of death worldwide. Research efforts are therefore focused on finding new and specific
therapeutic targets for personalized therapies that take into account individual variability (Collins
and Varmus, 2015). However, precision medicine requires the use of precision drugs able to act
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only on the molecular determinant driving the specific
disease, without producing adverse side effects. Thus, in
recent years the drug discovery process has contributed to
scientific advancements (Drews, 2000) by identifying novel small
molecules with anticancer activity. High-throughput screening
provides a new approach to drug discovery, allowing the
screening of large libraries of heterogeneous compounds and the
evaluation of their target modulation and biological effect. Cell
death impairment is one of the six hallmarks of human cancer
(Hanahan and Weinberg, 2000, 2011). A cancer cell retains the
ability to undergo apoptosis, but signal transduction pathways are
often silenced and therefore inactive. The remarkable potential
of epigenetic drugs used in epigenetic therapy is their ability
to reactivate these signals by correcting epigenetic defects. The
last few years have seen growing scientific interest in the search
for epi-targets to be exploited in diagnostics, prognostics and
therapeutics. In addition, specific nutrients involved in different
metabolic processes have been investigated as potential targets
of anticancer drugs (Cheong et al., 2012; DeBerardinis and
Chandel, 2016; Kalyanaraman, 2017). Iron, for example, is
present inside cells in two main oxidation states, ferric (Fe2+)
and ferrous (Fe3+), and is necessary for oxygen transport, energy
transduction, macromolecule biosynthesis, and cell proliferation
(Andrews, 2008; Pantopoulos et al., 2012). The rapid growth of
tumor cells requires a large amount of iron, and the dysregulation
of iron metabolism with increased uptake and decreased storage
contributes to cancer progression. Recent studies show the
exciting potential role of iron chelators in anticancer treatments
(Richardson, 2002; Buss et al., 2003; Hatcher et al., 2009).
The siderophore deferoxamine (DFO) was the first molecule
with a chelating mechanism used for thalassemia (Olivieri et al.,
1998), and was later evaluated in clinical trials to assess its
antiproliferative activity mediated by blocking G0/S phases for
the treatment of neuroblastoma and leukemia (Lovejoy and
Richardson, 2002; Richardson, 2005). However, DFO has two
major drawbacks: oral inactivity due to hydrophilicity and a short
half-life. Consequently, new compounds were developed as an
alternative to DFO for cancer treatment, including deferiprone
(DFP) (Jamuar and Lai, 2012; Martin-Bastida et al., 2017),
triapine (Richardson, 2002; Myers et al., 2011) and hydrazones.
Pyridoxal isonicotinoyl hydrazone (PIH) is a tridentate chelator
which binds iron by carbonyl and phenolic oxygen, and imine
nitrogen (Buss et al., 2002), with a ligand/iron ratio of 2:1.
PIH was shown to act in cells by inhibiting DNA synthesis,
as does DFO, but with greater efficiency (Richardson et al.,
1995; Richardson and Ponka, 1998), principally as a result of
its increased lipophilicity, which allows better penetration of the
plasma membrane (Lovejoy and Richardson, 2003).
Here, by screening 23 commercial molecules we better
characterized a PIH derivative, 3-chloro-N′-(2-hydroxybenzy-
lidene)benzohydrazide (CHBH), known to be a lysine-specific
histone demethylase 1A (LSD1) inhibitor (Sorna et al., 2013).
LSD1 was the first enzyme found able to demethylate lysines 4
and 9 in histone H3 (Hayward and Cole, 2016; Maiques-Diaz and
Somervaille, 2016) via a flavin-dependent monoamine oxidase
mechanism (Forneris et al., 2005), thereby regulating gene
expression (Miao and Natarajan, 2005; Cheng and Zhang, 2007).
LSD1 is overexpressed in several human cancer cell lines (Kahl
et al., 2006; Lim et al., 2010; Hayami et al., 2011; Niebel et al., 2014;
Chen et al., 2017; Zou et al., 2017). We found that CHBH is able
to induce cell proliferation arrest in a number of human cancer
cell lines, including lung, colon, pancreas and breast cancer, while
sparing normal cells.
Our findings show that CHBH is able to induce selective
cancer cell death through both chromatin modulation and




Cell lines were tested and authenticated following the
manufacturer’s instructions: DSMZ for NB4 and ATCC for
all the others. HCT-116 and HT-29 (colon cancer), MCF7 (breast
cancer), A549 (lung cancer), MiaPaCa (pancreas carcinoma),
and A2058 (melanoma) cells were propagated in Dulbecco’s
modified Eagle’s medium (Euroclone, Milan, Italy) with 10%
fetal bovine serum (FBS) (Euroclone), 2 mM L-glutamine
(Euroclone) and antibiotics (100 U/ml penicillin, 100 mg/ml
streptomycin; Euroclone). NB4 (acute promyelocytic leukemia)
and K562 (chronic myelogenous leukemia) cells were propagated
in RPMI-1640 medium containing 4.5 g/L glucose (Euroclone)
supplemented with 10% FBS (Euroclone), 100 U/mL penicillin–
streptomycin (Euroclone) and 2 mM L-glutamine (Euroclone).
MRC5 (normal human lung) cells were propagated in Eagle’s
minimum essential medium (Euroclone) supplemented with
10% FBS (Euroclone), and 10 µg/ml gentamicin solution
(Euroclone).
Cell Cycle and Cell Death Analysis
HCT-116 and NB4 cells were treated for 24 and 72 h with
CHBH (25 µM), or with SAHA (5 µM) or PKF118-310 (1 µM),
used as positive controls of cell death. After treatment, cells
were collected, then centrifuged (1,200 rpm for 5 min) and
suspended in a solution containing 1X PBS, 0.1% sodium citrate,
0.1% NP40, and 50 mg/mL propidium iodide. After 20 min of
incubation at room temperature in the dark, cell cycle and cell
death were evaluated by FACS (FACSCalibur, BD Biosciences,
San Jose, CA, United States) and analyzed by FACS with Cell
Quest Pro software (BD Biosciences). Cell death was measured
as a percentage of cells in pre-G1 phase.
MTT Assay
The viability of cells was determined using the standard MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
assay. Briefly, 5 × 104 cells/well were plated in a 24-well plate
and treated, in triplicate, with CHBH at different concentrations
for 24 and 72 h. MTT solution was added for 3 h at 0.5 mg/mL,
the purple formazan crystals were dissolved in DMSO (Sigma-
Aldrich, St. Louis, MO, United States) and the absorbance was
read at a wavelength of 570 nm with a TECAN M-200 reader
(Tecan, Männedorf, Switzerland).
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Protein Histone Extraction
HCT-116 cells were treated with 25 µM CHBH for 24 and 48 h.
After treatment, cells were harvested and washed twice with PBS
(Euroclone). Cells were then lysed in triton extraction buffer
(TEB) containing PBS with 0.5% Triton X-100 (v/v), 2 mM
phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3 at a
cell density of 107 cells/mL for 10 min on ice and centrifuged
(2,000 rpm at 4◦C for 10 min). The supernatant was removed
and the pellet washed in half the volume of TEB and centrifuged
another time. The pellet was suspended in 0.2N HCl overnight at
4◦C on a rolling table. The samples were centrifuged at 2,000 rpm
for 10 min at 4◦C and the supernatant recovered. The histone
protein was determined using a Bradford assay (Bio-Rad, Milan,
Italy).
Western Blotting
Western blotting analysis was performed following the
recommendations of antibody suppliers and loading 8 µg
of histone extracts on 15% polyacrylamide gels. Antibodies
used were: H3K9me2, H3K27me3, H3K4me3, and H3K9/14ac
(Diagenode, Liège, Belgium); histone H4 (Abcam, Cambridge,
United Kingdom). Semi-quantitative analysis was performed
using ImageJ software.
Enzymatic Assay
CHBH activity on KDM4A enzyme was evaluated by KDM4A
Inhibitor Enzymatic Assay Kit (Epi-C srl, Naples, Italy). CHBH
was incubated for 30 min at 37◦C with 13.5 µL buffer, 6 µL
substrate and 4.5 µL human recombinant protein in a 96-
well black half-area plate. Next, 24 µL developer 1 solution
and 6 µL developer 2 solution were added in each well. After
30 min at room temperature the fluorescence was read with a
TECAN M-200 reader at excitation wavelength of 370 nm and
emission wavelength of 470 nm. The experiment was performed
in triplicate.
EnSpire Binding Assay
KDM4A-GST enzyme was purified by Escherichia coli BL21
bacteria after transfection with PGEX-4T-1-KDM4A plasmid.
One bacterial colony was grown in LB Broth medium (Sigma-
Aldrich) supplemented with antibiotics (100 µg/mL ampicillin)
in a shaking incubator overnight. When optical density was in
a range between 0.6 and 0.8, protein expression was induced
by isopropyl-β-D-1-thiogalactopyranoside (AppliChem, Milan,
Italy) at 200 µM concentration for 7 h. The bacteria were lysed
by sonication (Bioruptor, Diagenode) in lysis buffer containing
PBS with 1 mM dithiothreitol (DTT) (AppliChem), 0.5 mM
PMSF (AppliChem) and mini protease inhibitor cocktail (PIC)
1x (Roche, Monza, Italy). The enzyme was purified using a
GSTrap 4B column (GE Healthcare Life Sciences, Milan, Italy).
The purified recombinant KDM4A (40 mg/mL) was then dialysed
in water solution (100 mM NaCl, 1 mM DTT, 50 mM sodium
acetate pH 6.0). For the binding assay, the enzyme was diluted
in sodium acetate solution (20 mM pH 6.0) to obtain a final
concentration of 150 µg/mL, and 15 µL of this solution was
put in 384 high-performance optical microplate wells. The plate
was centrifuged at 800 rpm for 1 min and incubated overnight
at 4◦C. The following day, the immobilized enzyme was washed
four times using 25 µL PBS, centrifuging the plate at 800 rpm for
1 min after each wash. After the last wash the plate was incubated
at room temperature for 3 h, and during the last 30 min was
placed in the EnSpire instrument (PerkinElmer, Milan, Italy) to
equilibrate before the binding assay. Next, the baseline was read
and 15 µL of either CHBH or positive or negative control was
added into the plate at 100, 50, and 25 µM (in PBS solution with
0.1% DMSO). Finally, the plate was reloaded into the EnSpire
instrument to start final reads.
Calcein-AM Assay
Chronic myelogenous leukemia K562 cells were loaded at a
density of 1 × 106/mL in normal medium and treated with
calcein-acetoxymethyl ester (calcein-AM) (Life Technologies,
Carlsbad, CA, United States) at 0.125 µM for 15 min at 37◦C
and 5% CO2. Cells were then washed three times with PBS and
three times with distilled water. The pellet was resuspended in
500 µL water, lysed by thermic shock and centrifuged for 30 min
at 1,300 rpm. The supernatant was recovered and the calcein
read using a TECAN M-200 reader in a 96-well black half-area
plate at excitation wavelength of 488 nm and emission wavelength
of 516 nm. Ammonium iron(III) sulfate dodecahydrate (AIS)
(Fluka, Bucharest, Romania) was added at 30 and 100 µM final
concentration to quench the calcein. CHBH and positive control
(EDTA) at 100 µM were co-administered with AIS to evaluate
iron-chelating activity (Cabantchik et al., 1996; Epsztejn et al.,
1997; Konijn et al., 1999).
Statistical Analysis
Data were presented as the mean ± SD of biological triplicates.
Differences between the treatment groups and controls were
compared using one-way analysis of variance (ANOVA) and
Dunnett’s multiple-comparison test. Differences between groups
were considered to be significant at a p- value of < 0.05. Statistical
analyses were performed using GraphPad Prism 6.0 software
(GraphPad Software, Inc., San Diego, CA, United States).
RESULTS
CHBH Induces Cell Death in Human
Cancer Cell Lines
We screened a panel of 23 synthetic compounds (Supplementary
Figure S1) for their cytotoxic activity in two human cancer
cell lines, and identified CHBH as a promising anticancer
drug candidate (Figure 1A). Colon cancer HCT-116 and acute
promyelocytic leukemia NB4 cells were left untreated or treated
at the indicated times with 25 µM CHBH (Figures 1B,C)
and with two well-characterized anticancer drugs, SAHA and
PKF118-310 (Nebbioso et al., 2005; Franci et al., 2017). After
incubation, cell cycle progression was determined by FACS
analysis. Our data revealed that CHBH affected HCT-116
distribution over cell cycle phases within 48 h, reducing G1
phase and increasing S phase (Figure 1B). Furthermore, CHBH-
induced cell death, expressed as a percentage of cells in pre-G1
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FIGURE 1 | Impact of CHBH on cell cycle of HCT-116 and NB4 cells.
(A) Chemical structure of CHBH; (B,C) FACS analysis showing that CHBH
impairs cell cycle progression and induces cell death in HCT-116 and NB4
cells. The total amount of cells in G1, S, G2/M, and pre-G1 is 100%. Values
are mean ± SD of biological triplicates.
phase, increased in a time-dependent manner. Compared to
untreated cells, CHBH induced increased cell death at 48 h,
although not to the same level as PKF118-310 (≈20 vs. ≈70%,
respectively).
In the NB4 cell line, CHBH had a marked impact on cell
cycle progression after 24 h, inducing a robust (≈80%) cell
death similar to or higher than that mediated by PKF118-
310 and SAHA, respectively (Figure 1C). Taken together, these
initial findings strongly suggest a promising CHBH-mediated
antiproliferative effect in these two solid and hematological
cancer cell systems.
To better investigate CHBH cytotoxicity, we tested the
viability of other human cancer cell lines after exposure to the
compound (Figure 2). By MTT colorimetric assay, we evaluated
the effect of different doses of CHBH in MCF7 (breast), A549
(lung), MiaPaCa (pancreas), A2058 (melanoma), and HT-29
(colon) cancer cell lines after 24 and/or 72 h treatment. The
viability of all cell lines was affected by CHBH incubation in a
time- and dose-dependent manner. As shown by IC50 values at
72 h, colon cancer HT-29 cells were the most sensitive (IC50
≈0.95 µM; Figure 2E), followed in decreasing sensitivity by A549
(IC50 ≈2.4 µM; Figure 2B), A2058 (IC50 ≈6.5 µM; Figure 2D),
and MiaPaCa (IC50 ≈9.5 µM; Figure 2C) cell lines. In breast
cancer MCF7 cells, CHBH displayed moderate cytotoxicity with
IC50 ≈48 µM (Figure 2A). Interestingly, no significant effect
on viability was observed in the MRC5 normal lung cell line.
Even when MRC5 cells were exposed to the highest dose of
CHBH, no significant difference was observed, compared to the
control (Figure 2F). Normal cell viability was not affected as it
was in the other cell lines, suggesting that the CHBH-induced
antiproliferative effect may be a cell type-independent cancer
response, occurring both in hematological and solid cancer cell
lines but not in normal cells.
CHBH Impairs Histone Methylation and
Acetylation Levels
We next performed Western blotting analysis to confirm that
CHBH acts as an inhibitor of LSD1 enzyme. HCT-116 cells
were treated with 25 µM CHBH for 24 and 48 h, and levels
of H3K4me3, H3K9me2, and H3K27me3 were determined on
histone extracts (Figure 3A). LSD1 inhibition resulted in a
general gain of histone H3 methylation. Specifically, CHBH
treatment induced in a time-dependent manner an increase in
H3K4me3 peaking at over sevenfold at 48 h and an increase
in H3K9me2 at over fivefold at 24 h. Furthermore, H3K27me3
signal increased by and remained stable at twofold within
48 h. Consistent with the above findings, CHBH treatment
reduced global acetylation levels of histone H3 (Figure 3A, right
panel), highlighting CHBH-induced chromatin modulation. We
obtained similar findings in other solid (A549; Figure 3B)
and hematological (NB4; Figure 3C) cancer cell lines. Given
the strong impact of the compound on cell cycle progression
(Figure 1C), NB4 cells were treated with 10 µM CHBH for 24 h.
Taken together, these data indicate that, via LSD1 inhibition,
CHBH triggers wide-ranging histone alterations responsible for
the activation or repression of specific loci. Further investigations
will be required to understand which genes are involved in the
response to CHBH.
KDM4A Is Not a Target of CHBH
To better characterize the enzymatic selectivity of CHBH, we
investigated its ability to inhibit another lysine demethylase,
KDM4A, by using an in vitro enzymatic assay (Figure 4A)
and a binding assay (Figure 4B). We performed the in vitro
enzymatic assay for KDM4A as described in Franci et al. (2017).
Briefly, KDM4A-mediated H3K9me3 demethylation leads to
formaldehyde production. The reaction between formaldehyde,
ammonia, and acetoacetanilide produces a fluorescent adduct
which is detected at excitation wavelength of 370 nm and
emission wavelength of 470 nm. If the compound under
investigation acts as an inhibitor, the reaction is blocked and
the fluorescence signal decreases. As reported in Figure 4A, we
tested KDM4A activity against 10 different concentrations of
CHBH, ranging from 400 to 0.78 µM. Unlike PKF118-310, our
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FIGURE 2 | Impact of CHBH on cell proliferation. (A–E) Cell growth rates determined by MTT after treatment with indicated concentrations of CHBH for 24 h (gray
bars) and 72 h (black bars) show its anticancer activity. IC50 values show different cellular sensitivity to CHBH; (F) CHBH did not affect cell viability of normal MRC5
cells. Absorbance was read at a wavelength of 570 nm. Values are mean ± SD of biological triplicates. ∗∗∗∗p-value ≤ 0.0001, ∗∗∗p-value ≤ 0.001, ∗∗p-value ≤ 0.01,
∗p-value ≤ 0.05, ns p-value > 0.05 vs. control cells.
positive control of inhibition, CHBH treatment did not result in
significant modulation of KDM4A activity.
We confirmed these results by evaluating the binding between
CHBH and KDM4A by EnSpire label-free biochemical assay
(Figure 4B). This technique allows the detection of interactions
in real time by measuring the change in wavelength of refracted
light in response to binding between KDM4A, previously
immobilized onto a plate, and the molecules being tested. The
difference in wavelength (measured in picometers) is reported
as the response. As shown in Figure 4B, incubation of CHBH
in wells containing immobilized KDM4A resulted in minimal
response compared to the changes in wavelength observed in
presence of the positive control at the same concentration. CHBH
response was similar to the negative control. These data confirm
that CHBH does not act on KDM4A enzyme and indicate that the
compound is a selective inhibitor of LSD1.
CHBH Dequenches Calcein–Iron
Complex
Since CHBH is a derivative of PIH, we investigated its activity
as an iron chelator in order to better assess its anticancer
cytotoxicity. We evaluated the ability of CHBH to scavenge iron
by measuring intracellular fluorescence with the iron-sensitive
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FIGURE 3 | Impact of CHBH on methylation and acetylation levels of histone H3. Western blot analysis of expression levels of H3K4me3, H3K9me2, H3K27me3,
and H3K9/14ac in (A) HCT-116 (B) A549 and (C) NB4 cells after treatment with CHBH at indicated times and concentrations. H4 antibody was used for protein
normalization. Values are mean ± SD.
probe calcein (Figure 5). Chronic myelogenous leukemia K562
cells were treated according to the basic concepts of calcein
fluorescence assay (Cabantchik et al., 1996) to determine the
iron-chelating ability of CHBH to sequester iron from cells.
Specifically, K562 cells were treated with the cell-permanent
dye calcein-AM, which is converted inside the cell to a
green-fluorescent calcein, detected at excitation wavelength of
488 nm and emission wavelength of 516 nm. We observed
that calcein fluorescence was quenched by iron addition in a
dose-dependent manner. CHBH fully restored the quenching
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FIGURE 4 | CHBH does not target KDM4A. (A) KDM4 activity evaluated by
in vitro enzymatic assay in presence of 10 different concentrations of CHBH.
PKF118-310 at 10 µM was used as positive control. (B) Binding between
KDM4A and CHBH evaluated by EnSpire label-free biochemical assay. The
response was measured in picometers (pm) as the difference in wavelength.
Values are mean ± SD of biological triplicates. ∗∗∗∗p-value ≤ 0.0001, ns
p-value > 0.05 vs. control.
of calcein fluorescence by iron to a similar degree to that of
the positive control, EDTA. This finding shows that CHBH is a
strong iron-chelating agent, accounting - at least in part - for its
antiproliferative action in the cancer cell lines investigated in this
study.
DISCUSSION
The six hallmarks of cancer defined by Hanahan and Weinberg as
capabilities acquired during malignant transformation that allow
cancer cells to survive, proliferate, and disseminate (Hanahan
and Weinberg, 2000, 2011) are the main targets of current
anticancer therapies. The definition of cancer hallmarks has made
a significant contribution to the rapid growth of drug discovery
research into new molecules able principally to induce cancer
cell death. In recent years, small molecule drug discovery in
the field of oncology has focused on identifying compounds
with well-characterized mechanisms of action (Fouad and Aanei,
2017; Hyman et al., 2017). However, the increased awareness
FIGURE 5 | Dequenching of calcein–iron complex by CHBH. Fluorescence
assay of K562 cells treated with calcein-AM, (NH4)2Fe(SO4)2, DMSO
(negative control), EDTA (positive control) and CHBH at the indicated time.
The iron-chelating property of CHBH is comparable to that of EDTA. Values
are mean ± SD of biological triplicates.
that effective cancer treatment is highly dependent on drug
combinations has driven the development of drugs that are
simultaneously able to affect different biological processes in
order to optimize clinical benefits for patients (Hoelder et al.,
2012). The recognition that cancer hallmarks are orchestrated
by aberrant epigenetic alterations and the fact that many of
these alterations are druggable has propelled the discovery of
small molecules targeting different classes of epigenetic enzymes
(Falahi et al., 2014; Schnekenburger et al., 2016). Therapeutic
strategies using epigenetic drugs, which control several biological
processes, provide a multi-target approach against the hallmarks
of cancer (Kelly et al., 2010; Nebbioso et al., 2011; Block et al.,
2015).
We screened a number of commercially available molecules
for their potential cytotoxic activity in solid and hematological
cancer cell lines, and identified CHBH as a compound able to
affect chromatin structure as well as iron metabolism. CHBH
reduced the viability of a panel of cancer cell lines with
IC50 values in the micromolar range, suggesting its beneficial
application in multiple settings. Interestingly, we found that
CHBH did not affect the viability of a normal cell line. Thus,
we provide promising initial evidence that CHBH is cytotoxic
for cancer cells but not for normal cells. CHBH is known to
be an inhibitor of LSD1. LSD1 is a demethylase that converts
H3K4me2 or H3K9me2 into mono- or unmethylated forms,
inhibiting the expression of its target genes (Shi et al., 2004;
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Amente et al., 2013; Hyun et al., 2017). When inhibited, LSD1
increases H3K4 methylation levels leading to the expression
of tumor suppressor genes (Rotili and Mai, 2011; Jin et al.,
2013). LSD1 is overexpressed in several human cancer cells,
indicating its key role in tumor cell growth and survival (Hayami
et al., 2011; Liu et al., 2018). We therefore speculated that
CHBH may exert its anticancer action by inhibiting LSD1
activity. Consistent with this hypothesis, our findings showed
that CHBH treatment results in a general increase in histone
H3 methylation levels followed by a reduction in H3 acetylation
levels. The effects of CHBH on methylation and acetylation
levels of histone H3 correlated with its impact on HCT-116
viability at 24 and 48 h. Further research is necessary to
determine which genes are regulated upon CHBH-mediated
chromatin remodeling in order to identify oncogenes and tumor
suppressor genes responsible for CHBH-induced cell death. In
addition, data from our KDM4A studies showed that CHBH
may be an LSD1-selective inhibitor. This property would make
it a suitable candidate for future studies investigating the
role of LSD1 in both biological processes and LSD1-driven
diseases.
Cell death can also be due to altered iron metabolism (Torti
and Torti, 2013). Iron levels increase in cancer cells, thereby
sustaining their growth and survival (Manz et al., 2016). By
fluorescence assay, we demonstrated that CHBH, a derivative
of PIH, is an iron-chelating agent with comparable efficacy to
EDTA, thus pointing to its dual anticancer action. Our findings
provide initial evidence that the cancer-selective cytotoxic effect
of CHBH is due partly to the rearrangement of chromatin
by LSD1 inhibition, which may lead to reactivation of tumor
suppressor genes, and partly the removal of iron from cancer
cells as a result of its iron-chelating property. Both actions
require further clarification to gain a greater insight into the
molecular mechanisms underlying the antioncogenic effects of
CHBH. In conclusion, we show for the first time that this
compound strongly reduces cancer cell proliferation both by
impairing iron metabolism and modulating chromatin structure
via LSD1-selective inhibition. One of the emerging challenges
in pharmacology is indeed the design of small molecules able
to inhibit simultaneously several molecular targets in malignant
transformation, where a plethora of altered pathways determine
the hallmarks of cancer (Alvarez et al., 2011; Nebbioso et al., 2011;
Ganesan, 2016). The use of a single drug eliciting two different
effects may represent a promising approach for cancer therapy
and overcome the drawbacks of combination therapies in terms
of drug resistance, toxicity, and side effects.
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FIGURE S1 | Cytotoxic activity of a panel of 23 synthetic compounds. FACS
analysis of 23 compounds screened in (A,B) HCT-116 and (C) NB4 cell lines.
SAHA and PKF118-310 were used as controls. The total amount of cells in G1, S,
G2/M, and pre-G1 is 100%. Values are mean ± SD of biological triplicates.
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